The weight reduction that accompanies a VLCD is an effective treatment for type 2 diabetics, a condition closely associated with and exacerbated by obesity. Weight loss is associated with reductions in insulin resistance, pro-inflammatory markers, and may even improve insulin secretion. These improvements treat the key defects underlying the pathophysiology of type 2 diabetes. For many patients oral hypo-glycemic medications and insulin can be reduced or discontinued at the onset of a VLCD and normal blood glucose levels are seen after the first month.